Literature DB >> 6370860

Biosynthetic capacity for type-specific antigen synthesis determines the virulence of serotype III strains of group B streptococci.

M K Yeung, S J Mattingly.   

Abstract

The level of type-specific antigen (that covalently associated with the cell wall peptidoglycan and that released extracellularly) synthesized by virulent and avirulent strains of type III group B streptococci was quantitated and compared. Additionally, the effect of the physiological age of the cells and the influence of the exogenous phosphate ion concentration on the level of antigen synthesis by these organisms were also examined. Approximately 4% of the total antigen synthesized by the organism is noncovalently bound to the cell surface, and the difference in level of the noncovalently associated type-specific antigen between virulent and avirulent strains was negligible. In contrast, when the cell-associated covalently bound type antigens were evaluated, virulent strains were demonstrated to have two- to threefold higher levels than those of avirulent strains during the exponential and stationary phases of growth under various growth conditions. Furthermore, virulent strains that had high levels of cell-associated type antigen also secreted more extracellular type antigen than did avirulent strains. Thus, the data were consistent with the hypothesis that an overall production of type-specific antigen correlated with virulence in mice. However, the cell-associated type-specific antigen probably represented a better indicator for virulence potential since the addition of purified extracellular type-specific antigen to a mutant strain that lacks cell surface type antigen did not alter the 50% lethality value of the organism. To account for variation in the level of type-specific antigen produced by these strains, the kinetics of both the group- and type-specific antigens synthesis was investigated at the cell membrane level by utilizing an intact protoplast system.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6370860      PMCID: PMC263503          DOI: 10.1128/iai.44.2.217-221.1984

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  23 in total

1.  Strain specificity of opsonins for group B streptococci types II and III.

Authors:  A O Shigeoka; R T Hall; H R Hill
Journal:  Infect Immun       Date:  1979-02       Impact factor: 3.441

2.  A manual of quantitative immunoelectrophoresis. Methods and applications. 1. General remarks on principles, equipment, reagents and procedures.

Authors:  B Weeke
Journal:  Scand J Immunol Suppl       Date:  1973

3.  Circulating polyribophosphate in Hemophilus influenzae, type b meningitis. Correlation with clinical course and antibody response.

Authors:  R J O'Reilly; P Anderson; D L Ingram; G Peter; D H Smith
Journal:  J Clin Invest       Date:  1975-10       Impact factor: 14.808

4.  Growth of several cariogenic strains of oral streptococci in a chemically defined medium.

Authors:  B Terleckyj; N P Willett; G D Shockman
Journal:  Infect Immun       Date:  1975-04       Impact factor: 3.441

Review 5.  Microbial surfaces in relation to pathogenicity.

Authors:  H Smith
Journal:  Bacteriol Rev       Date:  1977-06

6.  Factors influencing release of type III antigens by group B streptococci.

Authors:  T I Doran; D C Straus; S J Mattingly
Journal:  Infect Immun       Date:  1981-02       Impact factor: 3.441

7.  Chicken embryo model for type III group B beta-hemolytic streptococcal septicemia.

Authors:  J Tieffenberg; L Vogel; R R Kretschmer; D Padnos; S P Gotoff
Journal:  Infect Immun       Date:  1978-02       Impact factor: 3.441

8.  Mouse protection test for group B Streptococcus type III.

Authors:  R S Baltimore; D L Kasper; J Vecchitto
Journal:  J Infect Dis       Date:  1979-07       Impact factor: 5.226

9.  Production of bacteremia and meningitis in infant rats with group B streptococcal serotypes.

Authors:  P Ferrieri; B Burke; J Nelson
Journal:  Infect Immun       Date:  1980-03       Impact factor: 3.441

10.  Multiple mouse-protective antibodies directed against group B streptococci. Special reference to antibodies effective against protein antigens.

Authors:  R C Lancefield; M McCarty; W N Everly
Journal:  J Exp Med       Date:  1975-07-01       Impact factor: 14.307

View more
  13 in total

1.  Differential expression of Vibrio vulnificus capsular polysaccharide.

Authors:  A C Wright; J L Powell; M K Tanner; L A Ensor; A B Karpas; J G Morris; M B Sztein
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

2.  Novel coagglutination method for serotyping group B streptococci.

Authors:  S Håkansson; L G Burman; J Henrichsen; S E Holm
Journal:  J Clin Microbiol       Date:  1992-12       Impact factor: 5.948

3.  The potential use of monoclonal antibodies as therapeutic modalities in neonatal infection.

Authors:  H R Hill; L A Gonzales; D K Kelsey; H V Raff
Journal:  Clin Rev Allergy       Date:  1992 Spring-Summer

4.  Decreased capacity for type-specific-antigen synthesis accounts for high prevalence of nontypeable strains of group B streptococci in Mexico.

Authors:  G C Palacios; E K Eskew; F Solorzano; S J Mattingly
Journal:  J Clin Microbiol       Date:  1997-11       Impact factor: 5.948

5.  Stimulation of complement component C3 synthesis in macrophagelike cell lines by group B streptococci.

Authors:  K J Goodrum
Journal:  Infect Immun       Date:  1987-05       Impact factor: 3.441

6.  Capsular polysaccharide regulates neutrophil complement receptor interactions with type III group B streptococci.

Authors:  M S Edwards; M R Wessels; C J Baker
Journal:  Infect Immun       Date:  1993-07       Impact factor: 3.441

7.  Identification of a high-virulence clone of type III Streptococcus agalactiae (group B Streptococcus) causing invasive neonatal disease.

Authors:  J M Musser; S J Mattingly; R Quentin; A Goudeau; R K Selander
Journal:  Proc Natl Acad Sci U S A       Date:  1989-06       Impact factor: 11.205

8.  In vitro method to differentiate isolates of type III Streptococcus agalactiae from symptomatic and asymptomatic patients.

Authors:  J J Maurer; S J Mattingly
Journal:  J Clin Microbiol       Date:  1988-04       Impact factor: 5.948

9.  Molecular analysis of lipoteichoic acid from Streptococcus agalactiae.

Authors:  J J Maurer; S J Mattingly
Journal:  J Bacteriol       Date:  1991-01       Impact factor: 3.490

10.  Cell growth rate regulates expression of group B Streptococcus type III capsular polysaccharide.

Authors:  L C Paoletti; R A Ross; K D Johnson
Journal:  Infect Immun       Date:  1996-04       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.